CSL Limited
CSL
주식 순위
#363
CSL Limited operates as a global biopharmaceutical company, engaged in the... CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
주가
$137.83
시가총액
$66.14B
변동 (1일)
0.87%
변동 (1년)
-3.78%
국가
AU
거래 CSL Limited (CSL)
카테고리
Healthcare
CSL Limited (CSL)의 주가 이력
최고 종가: $130.93 (2026-10-01 기준)
최저 종가: $0.58 (1994-05-01 기준)
최저 종가: $0.58 (1994-05-01 기준)
CSL Limited의 주가 이력 (1994 ~ 2026)
연간 주가 성과
| 연도 | 성과 |
|---|---|
| 2026 (TTM) | -11.03% |
| 2025 | -33.22% |
| 2024 | -3.40% |
| 2023 | -7.34% |
| 2022 | -5.55% |
| 2021 | -4.35% |
| 2020 | 13.64% |
| 2019 | 48.92% |
| 2018 | 19.64% |
| 2017 | 51.86% |
| 2016 | -2.99% |
| 2015 | 3.42% |
| 2014 | 17.66% |
| 2013 | 7.48% |
| 2012 | 72.89% |
| 2011 | -9.64% |
| 2010 | 27.38% |
| 2009 | 31.88% |
| 2008 | -30.73% |
| 2007 | 91.54% |
| 2006 | 59.34% |
| 2005 | 39.55% |
| 2004 | 69.88% |
| 2003 | 10.97% |
| 2002 | -54.53% |
| 2001 | 23.69% |
| 2000 | 47.80% |
| 1999 | 54.18% |
| 1998 | 35.94% |
| 1997 | 57.11% |
| 1996 | 56.41% |
| 1995 | 57.26% |
| 1994 | 0.00% |
유사 기업 또는 경쟁사의 주가
| 회사 | 주가 | 변동률 1년% | 국가 |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $890.85 | 9.42% |
NL
|
|
| $757.24 | 7.63% |
CH
|
|
| $268.40 | -5.70% |
BE
|
